Trial: 201704069

A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION AND EXPANSION STUDY OF ENTRECTINIB (RXDX-101) IN PEDIATRICS WITH LOCALLY ADVANCED OR METASTATIC SOLID OR PRIMARY CNS TUMORS AND/OR WHO HAVE NO SATISFACTORY TREATMENT OPTIONS

Phase

I/II

Principal Investigator

Armstrong, Amy

Disease Site

Bones and Joints; Eye and Orbit; Ill-Defined Sites; Kidney; Liver; Melanoma, Skin; Other Digestive Organ; Other Endocrine System; Other Female Genital; Other Male Genital; Other Respiratory and Intrathoracic Organs; Other Skin; Soft Tissue; Stomach; Thyroid; Unknown Sites

Learn more about this study at: clinicaltrials.gov